title: Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.
abstract: Fourteen children with cystic fibrosis and pulmonary lung infection due to Pseudomonas aeruginosa were treated with piperacillin (300 mg/kg/day) alone or piperacillin and tobramycin (7 mg/kg/day) iv. The outcome with respect to clinical state, chest X-ray and lung function tests was better with combination therapy than with piperacillin alone. Bacteriological response was the same with both regimens: leucocyte content of the sputum decreased, non-mucoid Ps. aeruginosa strains were eliminated, but mucoid strains were only suppressed (11 children). Peak serum levels of piperacillin averaged 102 mg/l, the overall serum elimination was 0.75 h and the mean sputum concentrations ranged from 1.07 to 2.2 mg/l. Peak serum levels of tobramycin averaged 5.15 mg/l, the half life was 1.25 h and the mean sputum concentrations ranged from 0.57 to 0.68 mg/l. The clearance of piperacillin and tobramycin was increased significantly. Drug-resistance did not develop during therapy.
mesh_terms: D000293:Adolescent; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D004359:Drug Therapy, Combination; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy*; D014031:Tobramycin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014031:Tobramycin; D010878:Piperacillin